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Abstract 
In 2003 the Motor Neurone Disease (MND) Association, together with The Wellcome Trust, funded 
the creation of a national DNA Bank specific for MND. It was anticipated that the DNA Bank would 
constitute an important resource to researchers worldwide and significantly increase activity in MND 
genetic research. The DNA Bank houses over 3000 high quality DNA samples, all of which were 
donated by people living with MND, family members and non-related controls, accompanied by 
clinical phenotype data about the patients. Today the primary focus of the UK MND DNA Bank still 
remains to identify causative and disease modifying factors for this devastating disease.  
Keywords: Motor Neurone Disease (MND), Amyotrophic Lateral Sclerosis (ALS), Biobank. 
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Motor Neuron Disease (MND) is a fatal, rapidly progressive disease that affects the brain and spinal 
cord and which ultimately leads to respiratory failure around 2-5 years following symptom onset [1, 
2].  Approximately 1 in 300 people develop MND but its prevalence is low, at about 6-8 in 100,000 
because of short life expectancy [3]. There is no diagnostic test and treatment is largely palliative, 
with only one agent, riluzole, having a modest effect in extending survival. Genetic factors 
undoubtedly play a role in most cases of the disease, both in pathogenesis and rate of progression, 
with about 5-10% of all patients having a clear family history of MND and in some cases, 
frontotemporal dementia [4, 5, 6]. Over 100 genes have now been implicated in the causation of 
MND [7]. No consistent environmental risk factor has been identified, although it is possible that 
such factors may trigger disease in genetically susceptible individuals, and therefore it is plausible 
that apparent sporadic cases of MND will be genetically determined to some degree [8, 9].  
 
An essential starting point for successful genetic research is access to high quality samples, 
accompanied by detailed clinical information. Large-scale gene sequencing and association studies 
need many thousands of samples to be screened such that results are statistically significant. Access 
to such samples had become a major obstacle in exploring the pathogenesis of MND and the concept 
of a MND DNA Bank was born. The objectives of the initial study were threefold: 1) To collect 
cohorts of patient, parent/sibling and control samples from sporadic and familial MND; 2) To collect 
clinical information in order to examine susceptibility traits in clinical subgroups of MND; 3) To 
make this resource available to the international research community and to foster collaboration 
between research teams, in order to identify genetic risk factors for MND. 
ORGANISATIONAL STRUCTURE OF THE UK MND DNA BANK 
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The UK MND DNA Bank was a collaborative project adopting a ‘Hub and Spoke’ model, with three 
regional 'Hub' centres linking with a total of 16 ‘Spoke' centres (Table 1). Samples were obtained 
from sporadic and familial MND patients attending MND clinics in the UK, their spouses (or other 
genetically unrelated controls) and blood relatives. Samples within the UK MND DNA Bank are 
housed at CIGMR Biobank, at the University of Manchester. In addition, as one of the Public Health 
England collections, the European Collection of Cell Cultures (ECACC) manages the transformation 
and storage of EBV-transformed lymphocytes derived from blood samples from participants 
providing an everlasting supply of DNA for the Bank. 
 
The MND Association’s Biomedical Research Advisory Panel (BRAP) oversee the governance and 
the strategic development of the DNA Bank, ensuring that samples are utilised in an appropriate 
fashion, and that any clinical information requested is appropriate for the proposed study. The 
Technical Access Committee (TAC) at CIGMR Biobank, determine sample requirements for the 
technology platform to be used, the quantity of sample required and ensure any leftover samples are 
returned or destroyed. All applications for access to the samples are judged on merit. In order to 
receive material and clinical information from the DNA Bank, all applicants must agree to the terms 
and conditions of sample use (see supplementary info). This specifies the user and specific purpose 
for which the samples and data are to be licensed, including standard terms as to the ownership, 
exploitation and dissemination of results, and requirements that the user conforms to the terms of the 
participants' consent.   
 
SAMPLE COLLECTION, STORAGE AND QUALITY CONTROL 
Sample collection began in 2003. All participants were over 18 years of age. In order to ensure that 
the patient cohort was representative of disease prognosis, patients must have experienced symptom 
onset (significant muscle weakness) on or after January 2002. All patients fulfilled El Escorial 
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criteria for probable or definite Amyotrophic Lateral Sclerosis (ALS) [10]. Patients presenting with 
Progressive Muscular Atrophy (PMA), Primary Lateral Sclerosis (PLS) or Progressive Bulbar Palsy 
(PBP) were also included in the study. Patients were recruited by consultant neurologists with a 
specialist interest in MND in participating centres.  Patients participating in other clinical research 
projects were not excluded from the study. Blood samples were also collected from consenting 
partners/carers, providing some degree of matching in terms of age, education, environmental 
exposure and often ethnicity.  Where patients presented with familial MND, blood samples were 
collected from family members for linkage analysis. Where patients presented with sporadic MND, 
where possible, blood samples were also collected from parents or from a parent and sibling, to give 
so-called ‘Trio samples’ increasing the amount of genetic information available for researchers.  
 
Informed consent to participate was sought from all patients, family members and controls. Ethical 
approval for the collection of samples and the creation of the UK MND DNA Bank was given by the 
Trent Research Ethics Committee in February 2003 ref MREC/02/4/107 and in July 2009, ref 
09/HO405/32. Participants were provided with detailed information and contact details and could 
withdraw from the study at any time. The samples were pseudo-anonymised and an online clinical 
database was developed to facilitate data entry and collection by the research nurses and enable 
tracking of trends in clinical parameters such as symptom onset and presentation for data analysis.  
Storage and access to this data set is in accordance with the UK Data Protection Act 1998 [11]. 
 
Prior to 2010, DNA extraction from donated blood samples was carried out at individual Hub centres 
using the Nucleon BACC3 protocol (Amersham, UK). Extracted DNA was sent to CIGMR Biobank 
for long-term storage. On receipt, all DNA samples were run on 1% agarose gels alongside 
molecular weight markers of appropriate size to check integrity.  From August 2010, DNA extraction 
was carried out at CIGMR Biobank using automated robotic processing under ISO900:2000 
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operating standards.  In all cases, both when imported from Hub centres, or extracted by CIGMR 
Biobank themselves, DNA concentration was measured using a nanodrop spectrophotometer.  
Samples with OD ratios outside the normal range were removed from the cohort and contaminants 
washed using ethanol precipitation.  Final DNA concentration was measured using Quant-iT™ 
Picogreen® dsDNA Assay Kit (Invitrogen
TM
 Life Technologies, UK). Samples were measured on 96 
well plates, in triplicate against standards of known concentration for quality control.  
DNA aliquots are stored in 2D bar coded tubes for sample tracking purposes.  A relational database 
recorded the 2D barcodes associated with each patient/donor ID. All samples within the collection 
were screened for gender using PCR on presumed duplicate samples according to standard protocols. 
Samples with a mismatch between the expected gender as recorded in the patient information, and 
actual gender as confirmed by PCR, were rescreened using an alternative PCR method of gender 
identification based on the absence/presence of Alu sequence [12]. Any samples with a confirmed 
discrepancy were ring fenced from the collection and suspended from the in-house laboratory 
management system. 
 
Peripheral blood lymphocytes (PBLs) were isolated from whole blood samples at ECACC using 
density gradient centrifugation. An aliquot of untransformed PBLs was stored in liquid nitrogen for 
safekeeping, whilst the remaining PBLs were transformed using the Epstein Barr virus according to 
standard protocols [13]. The resulting lymphoblastoid cell lines were cryopreserved and are used to 
restock the DNA Bank when stock levels become low.  
 
4. THE UK MND DNA BANK 
In October 2012, at the end of the collection period, the UK MND DNA Bank comprised 3159 high 
quality DNA samples. Of these 1344 samples were taken from individuals diagnosed with sporadic 
MND (see figure 1A and 1B). There were 133 familial MND samples within the collection and a 
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further 500 samples taken from family members, including samples that form 28 parent trio sets and 
27 sibling trio sets. The remaining 1085 samples were taken from controls. In line with population-
based demographic for the disease [14] the breakdown of gender in the collection is around 60% 
male (Figure 1A). The average age of onset was approximately 62 years of age (Figure 1C). Each 
sample is accompanied by a minimum dataset of: age at which the samples were taken; gender; 
disease status; and where appropriate diagnostic certainty (El Escorial Status) and age of onset 
(calculated from date of birth and date of symptom onset). An extended dataset has been collected 
for as many participants as possible but it is not a complete dataset for the entire collection (see Table 
2). In total 2653 frozen lymphoblastoid cell lines are held in storage at ECACC following a PBL 
transformation success rate of 97%.  Of these, 1267 samples were generated from whole blood taken 
from patients with sporadic MND. 115 cell lines were generated from familial samples and the 
remaining 1058 cells lines have been established using blood samples obtained from control or 
family members (see Figure 1D).  
 
Table 3 shows the success rates for PCRs performed on the DNA samples within the collection. The 
failure rate of the quality control assay was less than 1.5% suggesting that the quality of DNA within 
the collection is very high. The gender results from these assays were directly compared to the 
gender recorded for individuals on the clinical database. Where there was a discrepancy between the 
expected gender and that determined in the assay, patient clinical notes were rechecked. In the 
absence of a clerical error, samples were rescreened using both the original AMEL marker and an 
alternative gender marker, the Human ALU expansion [12]. Sixty eight samples that continued to 
show a discrepancy between the expected gender and the assay gender were ring fenced from the 
collection and suspended from the laboratory management system. 
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The UK MND DNA Bank was designed to be available to the international research community. 
DNA samples from the bank represent an incident not prevalent population and are unlikely to be 
biased.  The fundamental guarantee that any DNA Bank must be able to give is that it can provide 
high quality DNA samples with good integrity and accompanying high quality clinical data. 
Understandably, a constraint of the DNA Bank is that the genomic DNA supply itself is limited and 
although cell lines have been established, the DNA from such cell lines may have sequence changes 
compared with the original genomic samples. This fact must be considered when choosing to use cell 
line derived DNA even if the DNA itself is of a high standard as demonstrated by the rigorous quality 
control assays in place. As part of the governance of the DNA Bank, the MND Association must 
ensure compliance with legal and regulatory requirements. The Association must also guarantee that 
the resource adheres to rigorous research standards and is used in the further understanding of motor 
neuron disease, this includes prioritising access to those parts of the DNA Bank that are limited in 
availability, clarifying intellectual property rights and disseminating the results that flow from it.  
 
To date more than twenty projects have withdrawn samples from the DNA Bank. DNA samples have 
been used in complex, technical protocols such as genotyping, gene sequencing and genome-wide 
association studies and numerous papers have been published or are in press [15, 16, 17, 18, 19, 20, 
21, 22, 23, 24, 25, 26, 27 and 28]. Importantly, projects using samples from the DNA Bank have 
directly led to the detection of several MND causing genes including C9orf72 and more recently 
Tub4A [15, 17, 22, 23 and 28]. With researchers now encouraged to publish in an open access format 
as part of the DNA Bank governance, and to deposit data from sequencing projects within accessible 
databases such as ALSOD: the Amyotrophic Lateral Sclerosis Online Database [7] and European 
Genome-Phenome archive [29], the dissemination and discussion of results by the research 
community is ensured.  In 2014 a proposal to perform whole genome sequencing on DNA samples 
from the UK MND DNA Bank as part of the international collaboration called Project MinE [30] 
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 8 
was approved. This exciting project will allow Next Generation Sequencing data to be collected from 
DNA Bank samples and shared across research groups.  The data will also confirm the accuracy of 
existing studies through imputation. It is hoped that sequencing DNA Bank samples will allow the 
identification of rare variants responsible for sporadic disease, continuously widening our knowledge 
about how genetic changes can contribute to MND. 
 
Ethical approval to extend the use of the cell lines beyond their original scope of providing an 
everlasting supply of DNA was granted in 2014 by the Derby- East Midlands Research Ethics 
Committee ref no. 14/EM/1088. This change in permission will potentially allow researchers to 
generate primary neuronal cultures and highly desirable induced pluripotent stem (iPS) cell lines 
from the cell lines stored at ECACC. The iPS cell lines could act as new disease models for drug 
screening and other potential treatments, as well as acting as tools for analysing downstream 
mechanisms involved in disease pathogenesis. Clearly the role of the DNA Bank in the governance 
of such samples will be paramount; it is simply not enough to provide high quality samples, but 
following how those samples have been used and ensuring the results are disseminated and discussed 
is the only way to ensure research continues to move forward. The original scope of the DNA Bank 
was to make a quantal difference in our understanding of MND and it is well on the way to fulfilling 
this promise. 
 
Acknowledgments: This project was supported by a programme grant from the Motor Neurone Disease 
Association (grant ref 6700). Information regarding the DNA Bank, including the terms and conditions for 
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creation of the UK MND DNA Bank was given by the Trent Research Ethics Committee in February 2003 ref 
MREC/02/4/107 and in July 2009, ref 09/HO405/32. Subsequent approval for the extended use of the cell 
lines within the DNA Bank was approved by the Derby- East Midlands Research Ethics Committee in Sept 
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FIGURE LEGENDS 
Table 1: Hub and Spoke Model for Sample Collection 
The UK MND DNA Bank was a collaborative project adopting a ‘hub and spoke’ model with three 
regional ‘hub centres’ linking with a total of 16 ‘spoke centres’. These included hospitals that are 
part of the MND Association’s Care Centre Network and centres which form part of the Department 
of Health / NIHR Dementias and Neurodegenerative Diseases Research Network (DeNDRoN).  The 
three Hub Centres were established at London (King’s College Hospital), Sheffield (Royal 
Hallamshire Hospital), and Birmingham (Queen Elizabeth Hospital). Recruitment to the study and 
sample collection was coordinated at the Hub centres by a DNA Bank Co-odinator based in London. 
Samples were obtained from sporadic and familial MND patients attending MND clinics in the UK, 
their spouses (or other genetically unrelated controls) and blood relatives. A DNA Bank research 
nurse was affiliated to each Hub centre to act as patient liaison, collect clinical information from 
patients, controls and family members, and take blood samples.  Laboratory Technicians were also 
employed at each Hub Centre to assist in the preparation of sample collection packs for participating 
satellite centres, DNA extraction and final sample storage. 
 
Figure 1:  The UK MND DNA Bank  
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The UK MND DNA Bank comprises 3159 high quality DNA samples. Of these 1344 samples were 
taken from individuals diagnosed with sporadic MND (see figure 1A and 1B). There were 133 
familial MND samples within the collection and a further 500 samples taken from family members, 
including samples that form 28 parent trio sets and 27 sibling trio sets. The remaining 1085 samples 
were taken from controls. In line with previous findings, where MND has been diagnosed, the 
breakdown of gender in the collection is around 60% male (Figure 1A). The average age of onset 
was approximately 62 years of age (Figure 1C). In total 2653 frozen lymphoblastoid cell lines are 
held in storage at ECACC. Of these 1267 samples were generated from whole blood taken from 
patients with sporadic MND. 115 cell lines were generated from familial samples and the remaining 
1058 cells lines have been established using blood samples obtained from control or family members 
(see Figure 1D).  
 
 
Table 2: Clinical information available from the UK MND DNA Bank 
Each sample withdrawn from the UK MND DNA Bank is accompanied by a minimum dataset of: 
age at which the samples were taken; gender; disease status; and where appropriate diagnostic 
certainty (El Escorial Status) and age of onset (calculated from date of birth and date of symptom 
onset). An extended dataset has been collected for as many participants as possible but it is not a 
complete dataset for the entire collection. The clinical information was collected by the Research 
Nurse using a brief clinical questionnaire. Identifying data was kept at each Hub centre in secure 
locations in accordance with the Data Protection Act. 
 
Table 3: Quality Control PCR Assay fail rate 
Quality control assays were carried out across the collection. In an initial analysis of the collection 
768 samples were screened using the ABI Identifiler kit. Following this, a further 2170 samples were 
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screened in a gender-based assay using the AMEL marker. Only 62 samples showed a continued 
discrepancy between the gender of the actual DNA sample and that stated in the clinical notes. 
Whilst this is still a low level of error for a collection of this size, the samples were ring fenced from 
the collection.  
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Figure 1: The UK MND DNA Bank Collection 
1A: MND status and gender of samples held in the DNA bank 1B: Diagnostic certainty of samples within the DNA bank 
1C: Age range of symptom onset within the DNA bank 1D: MND status and gender of cell line samples held at ECACC  
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Table 2 : Clinical information available from the UK MND DNA bank 
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Type of Assay  No. samples screened % Assay fail 
Abi Identifilier Kit - AMEL Marker 768 1.30 
Gender based PCR - AMEL 
marker 2750 0.62 
Total number of individuals 
screened to confirm gender  
% Gender error across 
collection 
3415 1.82 
Table 3 : Quality Control PCR fail rates 
Figure 3
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